Bhatt A, Rousset P, Benzerdjeb N, Kammar P, Mehta S, Parikh L, Goswami G, Shaikh S, Kepenekian V, Passot G, Glehen O
Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India.
Department of Radiology, Centre Hospitalier Lyon Sud, Lyon, France.
Colorectal Dis. 2020 Dec;22(12):2123-2132. doi: 10.1111/codi.15368. Epub 2020 Oct 16.
The peritoneal cancer index (PCI) is one of the strongest prognostic factors in patients undergoing cytoreductive surgery (CRS) for colorectal peritoneal metastases. Using pathological evaluation, however, the disease extent differs in a large proportion of patients. Our aim was to study the correlation between the radiological (rPCI), surgical (sPCI) and pathological (pPCI) PCI in order to determine factors affecting the discordance between these indices and their potential therapeutic implications.
From July 2018 to December 2019, 128 patients were included in this study. The radiological, pathological and surgical findings were compared. A protocol for pathological evaluation was followed at all centres.
All patients underwent a CT scan and 102 (79.6%) had a peritoneal MRI. The rPCI was the same as the sPCI in 81 (63.2%) patients and the pPCI in 93 (72.6%). Concordance was significantly lower for moderate-volume (sPCI 13-20) and high-volume (sPCI > 20) disease than for low-volume disease (sPCI 0-12) (P < 0.001 for sPCI; P = 0.001 for pPCI). The accuracy of imaging in predicting presence/absence of disease upon pathological evaluation ranged from 63% to 97% in the different regions of the PCI. The pPCI concurred with the sPCI in 86 (68.8%) patients. Of the nine patients with sPCI > 20, the pPCI was less than 20 in six.
The rPCI and sPCI both concurred with pPCI in approximately two thirds of patients. Preoperative evaluation should focus on the range in which the sPCI lies and not its absolute value. Radiological evaluation did not overestimate sPCI in any patient with high/moderate-volume disease. The benefit of CRS in patients with a high r/sPCI (> 20) who respond to systemic therapies should be prospectively evaluated.
腹膜癌指数(PCI)是接受结直肠腹膜转移细胞减灭术(CRS)患者最强的预后因素之一。然而,通过病理评估发现,很大一部分患者的疾病范围存在差异。我们的目的是研究放射学(rPCI)、手术(sPCI)和病理(pPCI)PCI之间的相关性,以确定影响这些指数不一致的因素及其潜在的治疗意义。
2018年7月至2019年12月,本研究纳入了128例患者。比较了放射学、病理和手术结果。所有中心均遵循病理评估方案。
所有患者均接受了CT扫描,102例(79.6%)进行了腹膜MRI检查。81例(63.2%)患者的rPCI与sPCI相同,93例(72.6%)患者的rPCI与pPCI相同。中等体积(sPCI 13 - 20)和大体积(sPCI > 20)疾病的一致性显著低于小体积疾病(sPCI 0 - 12)(sPCI为P < 0.001;pPCI为P = 0.001)。在PCI的不同区域,影像学预测病理评估中疾病有无的准确性在63%至97%之间。86例(68.8%)患者的pPCI与sPCI一致。在9例sPCI > 20的患者中,6例患者的pPCI小于20。
约三分之二患者的rPCI和sPCI均与pPCI一致。术前评估应关注sPCI所在范围而非其绝对值。对于任何高/中等体积疾病患者,放射学评估均未高估sPCI。对于r/sPCI高(> 20)且对全身治疗有反应的患者,CRS的益处应进行前瞻性评估。